Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “In Cycle 1 (28 days per cycle), subcutaneous (SC) AZA will be administered on Day 1, followed by oral AZA formulations and CED tablets on Days 2-7. In Cycle 2 and onward, oral AZA formulations and CED tablets will be administered on Day 1-7.”In the company’s words, NCT04608110 on ClinicalTrials.gov
- Tested for
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome (MDS)
- Main trialPhase 2/3
- “Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 Monotherapy is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 Monotherapy is a randomized open-label crossover study comparing the final…”In the company’s words, NCT04256317 on ClinicalTrials.gov
Other drugs for Myelodysplastic Syndromes
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- CrovalimabRoche · Phase 3
- DanicopanAlexion Pharmaceuticals, Inc. · Phase 3
- MomelotinibSierra Oncology LLC - a GSK company · Phase 2/3
- VenetoclaxAbbVie · Phase 3
Coming up2
- 1 Nov 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 1 Nov 2027 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | |
| Phase 1Recruiting | Dec 2027 | A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026